ArticleAnnals of surgical oncology2026
A Pathology-Based Model for Postoperative Recurrence or Metastasis Prediction and Adjuvant Immunotherapy Implications of Clear-Cell Renal Cell Carcinoma: A Multicenter, Retrospective Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundApproximately 30% of patients with clear cell renal cell carcinoma (ccRCC) experience recurrence after surgery, making it crucial to improve the prognosis for these patients. Stratification of patients with nonmetastatic ccRCC based on the risk of postoperative recurrence helps guide adjuvant immunotherapy after surgery. PATIENTS AND
methodsWe enrolled 2154 patients from two centers. Only patients without postoperative adjuvant therapy were used to analyze risk factors and construct models. A multivariable model was constructed to predict disease-free survival (DFS) and stratify patients. The log-rank test was used to examine the effects of immune checkpoint inhibitors (ICIs) and targeted therapy on DFS across different strata.
resultsWe identified seven independent risk factors: sex, microvascular invasion (MVI), T stage, pathological grade, sarcomatoid differentiation, necrosis, and capsular involvement. Using these characteristics, a prognostic model for nonmetastatic ccRCC was constructed. Using the constructed model, we stratified patients and validated stratification efficacy with DFS, overall survival (OS), and cancer-specific survival (CSS) as endpoints (all P < 0.001). With our model, we stratified patients who either received or did not receive postoperative adjuvant therapy and found that ICIs significantly improved DFS in high-risk patients. Compared with the current medication criteria in clinical trials for ICIs, our model demonstrated superior overall performance.
conclusionsWe identified seven crucial prognostic features influencing the prognosis of nonmetastatic ccRCC and developed a prognostic model using these features. On the basis of our model, we stratified patients and discovered that high-risk patients could benefit from treatment with ICIs.
Indexed as
Identifiers
42570984What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.